Gilead completes CymaBay acquisition but negative impact on 2024 EPS (NASDAQ:GILD) Markets March 22, 2024 [ad_1] Sundry Images/iStock Editorial through Getty Photographs Gilead Sciences (NASDAQ:GILD) has accomplished its $4.3B acquisition of CymaBay Therapeutics (NASDAQ:CBAY). Nonetheless,…
Gilead set to roll out Q4 results post-market Tuesday (NASDAQ:GILD) Markets February 6, 2024 [ad_1] jurgenfr Gilead Sciences (NASDAQ:GILD) is predicted to report the next This autumn revenue on decrease income Tuesday night, with…
